GlassScriptPhysician profile
Lindsey Jenks
NPI 1588151765
$4,991.73
in general payments reported to CMS, 2019-2025
45 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $610 · 2022: $1,540 · 2023: $1,930 · 2024: $912.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,841.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,841.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $647.56 | 2021-2024 | Mounjaro, Jardiance, Trulicity |
| Pfizer INC. | $535.84 | 2021-2024 | |
| Novo Nordisk INC | $509.10 | 2021-2024 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $363.02 | 2021-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $296.57 | 2021-2024 | Jardiance, Ofev |
| Glaxosmithkline, LLC. | $217.33 | 2023-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $193.09 | 2022-2024 | Repatha, Otezla, Evenity |
| Novartis Pharmaceuticals Corporation | $179.66 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $162.64 | 2021-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $155.79 | 2022 | |
| Abbott Laboratories | $141.17 | 2021-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Merck Sharp & Dohme LLC | $137.03 | 2022-2023 | Gardasil 9, Pneumovax 23, Vaxneuvance |
| Dexcom, INC. | $129.49 | 2021-2023 | Dexcom G6 Transmitter |
| Kowa Pharmaceuticals America, INC. | $93.25 | 2021-2023 | Seglentis, Livalo |
| Otsuka America Pharmaceutical, INC. | $92.10 | 2021-2024 | Nuedexta, Rexulti |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lindsey Jenks listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.